GlassScriptPhysician profile
Craig W Parson
NPI 1396192761
$7,460.96
in general payments reported to CMS, 2019-2025
28 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.11 · 2020: $366 · 2021: $1,596 · 2022: $1,206 · 2023: $1,103 · 2024: $1,754 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,952 · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,952.27 |
| Education | $265.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,300.22 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $889.76 | 2020-2025 | |
| Janssen Biotech, INC. | $606.07 | 2020-2025 | Tremfya |
| Pfizer INC. | $531.75 | 2020-2025 | |
| Arcutis Biotherapeutics, INC. | $510.59 | 2024-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $492.56 | 2022-2025 | Sotyktu |
| Ucb, INC. | $321.55 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $282.02 | 2021-2025 | Ilumya |
| Dermavant Sciences, INC. | $249.62 | 2023-2024 | Vtama |
| Genzyme Corporation | $184.85 | 2021-2025 | |
| Leo Pharma INC. | $176.49 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $150.95 | 2021-2024 | Otezla |
| Galderma Laboratories, L.P. | $131.98 | 2021-2025 | Aklief |
| Revance Therapeutics, INC. | $115.12 | 2025 | Daxxify |
| Vyne Pharmaceuticals INC. | $111.67 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $44.54 | 2025 | Vtama |
| Almirall LLC | $44.46 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.57 | 2021-2025 | Jublia, Cabtreo |
| Celgene Corporation | $40.14 | 2019 | |
| Mayne Pharma Commercial LLC | $37.44 | 2020-2021 | |
| Krystal Biotech INC | $32.87 | 2024-2025 | Vyjuvek |
| Organogenesis INC. | $31.68 | 2020 | |
| Botanix Sb INC | $31.10 | 2025 | Sofdra |
| Hill Dermaceuticals, INC. | $28.54 | 2025 | Tolak |
| Glaxosmithkline, LLC. | $25.08 | 2023 | Shingrix |
| Lilly USA, LLC | $17.86 | 2020 | |
| Merck Sharp & Dohme LLC | $17.26 | 2019 | |
| Journey Medical Corporation | $13.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Parson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.